Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven

Yahoo! FinanceRead the rest

Savara Reports First Quarter 2019 Financial Results and Provides Business Update

Yahoo! FinanceRead the rest

Savara Reports First Quarter 2019 Financial Results and Provides Business Update

BusinessWireRead the rest

Savara Inc. (SVRA) CEO Rob Neville on Q1 2019 Results – Earnings Call Transcript

Seeking AlphaRead the rest

Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis

AP NewsRead the rest

Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis

Yahoo! FinanceRead the rest

Investigating GM-CSF in aPAP: A Logical Replacement of a Dysfunctional Protein

CEO BlogRead the rest

Savara to Report First Quarter 2019 Financial Results and Provide Business Update

BusinessWireRead the rest

Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London

AccessWireRead the rest

Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection in People Living with Cystic Fibrosis

AccessWireRead the rest

Savara Inc. (SVRA) Q4 2018 Earnings Conference Call Transcript

NASDAQRead the rest

Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019

AccesswireRead the rest

Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

AccessWireRead the rest

Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development

MarketWiredRead the rest

Savara Inc. (SVRA) Can’t Burn Your Long Portfolio. Just Reaches 52-Week High

BZ WeeklyRead the rest

Savara Added to Nasdaq Biotechnology Index

MarketWiredRead the rest

Savara Receives $5 Million Award From Cystic Fibrosis Foundation Therapeutics to Advance MRSA Cure

EquitiesRead the rest

Savara nabs $5M award from CF nonprofit to support development of AeroVanc; shares up 4%

Seeking AlphaRead the rest

Savara (SVRA) Secures $5M Award from Cystic Fibrosis Foundation Therapeutics Inc. for Development of AeroVanc

Street InsiderRead the rest

Savara Receives $5 Million Award From Cystic Fibrosis Foundation Therapeutics, Inc. for the Development of AeroVanc

SavaraRead the rest

Savara’s (SVRA) CEO Rob Neville on Q3 2017 Results – Earnings Call Transcript

Seeking AlphaRead the rest

Savara Reports Third Quarter 2017 Financial Results and Provides Business Update

MarketWiredRead the rest

Savara Raises $47 Million in Stock and Warrant Deal

Equities.comRead the rest

Post-IPO Equity – Savara Pharmaceuticals

CrunchbaseRead the rest

Savara Announces Pricing of Public Offering of Common Stock

MarketWatchRead the rest

Savara Announces Expansion of Molgradex Development to Include Treatment of Nontuberculous Mycobacterial (NTM) Lung Infection

Digital JournalRead the rest

Savara Announces Expansion of Molgradex Development to Include Treatment of Nontuberculous Mycobacterial (NTM) Lung Infection

Marketwired OnlineRead the rest

Savara Starts Phase 3 Trial of AeroVanc for MRSA Lung Infections in Cystic Fibrosis

Cystic Fibrosis News TodayRead the rest

Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc

Pipeline ReviewRead the rest

Savara launches late-stage study of AeroVanc in CF patients with MRSA lung infections

Seeking AlphaRead the rest

Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc

MarketWiredRead the rest

Savara to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference on September 27th

MarketWiredRead the rest

Savara Reports Second Quarter 2017 Financial Results and Provides Business Update

MarketWiredRead the rest

Savara’s Aironite shows treatment effect in mid-stage pulmonary hypertension study; shares ahead 4%

Seeking AlphaRead the rest

Savara Set To Join Russell Microcap® Index

Cision PR NewswireRead the rest

Savara Announces Closing Of Public Offering Of Common Stock

GurufocusRead the rest

Savara Announces Pricing Of Public Offering Of Common Stock

Cision PR NewswireRead the rest

Savara (SVRA) Prices 8.4M Shares at $4.75

Steet InsiderRead the rest

Why Savara Inc (NASDAQ:SVRA) Is In Focus?

Financial TrendsRead the rest

Are Discerning Investors Interested in Savara Inc. (:SVRA)?

Evergreen CallerRead the rest

What You Should Know About Savara Inc (NASDAQ:SVRA)?

Financial TrendsRead the rest

Savara Inc (NASDAQ:SVRA) Reported Accelerated U.S. Molgradex Development Plan

Financial TrendsRead the rest

Savara Inc (SVRA) Is Preparing A Pivotal Phase-3 Study Of AeroVanc

Simply Wall StreetRead the rest

Savara Inc (NASDAQ:SVRA) Updates On U.S. Composition Of Matter Patent

Financial TrendsRead the rest

Tech Coast Angels Declares Record First Quarter; Angel Network Invests $3.8M in Q1 2017

For PR Web, click here

IRVINE, Calif. – May 11, 2017Tech Coast Angels (TCA) today announced that it had invested a total of $3.8 million in 17 total deals for the quarter ending March 31, 2017—its best Q1 in the angel network’s 20-year history both in dollars and number of companies invested.… Read the rest

Company with KU Roots Goes Public on NASDAQ

NewswiseRead the rest

BRIEF-Savara says will modify statistical analyses of its ongoing Impala study

ReutersRead the rest

Savara (SVRA) Announces Expedited Molgradex Development Strategy Following Guidance from FDA

StreetInsider.comRead the rest

Tech Coast Angels: How Savara Created A Winning Formula for Angel Investors and Company Success

PR WebRead the rest

Savara Announces Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc

PR NewswireRead the rest

SAVARA INC. (NASDAQ:SVRA) Files An 8-K Termination of a Material Definitive Agreement

Market ExclusiveRead the rest

North Texas Angel Network Announces Portfolio Company Savara’s Transition to the Public Market

PR WebRead the rest

Savara, Inc.’s Public Debut

Seeking AlphaRead the rest

BRIEF-Savara says has entered into a loan agreement with silicon valley bank

ReutersRead the rest

Savara Secures $15 Million Loan And Security Agreement With Silicon Valley Bank

Yahoo! FinanceRead the rest

Savara Announces Closing Of Merger With Mast Therapeutics

Yahoo! FinanceRead the rest

Savara Announces Closing Of Merger With Mast Therapeutics

Crossroads TodayRead the rest

Savara Announces Closing Of Merger With Mast Therapeutics

PR NewswireRead the rest

Mast Therapeutics Inc (NYSEMKT:MSTX) And Savara Update On Expected Merger Exchange Ratio

Financial TrendsRead the rest

Shareholders Have A Tough Decision To Make At Mast Therapeutics Inc (NYSEMKT:MSTX)

Insider FinancialRead the rest

BRIEF-Mast Therapeutics and Savara announce anticipated merger exchange ratio

ReutersRead the rest

Mast Therapeutics And Savara Announce Anticipated Merger Exchange Ratio

Yahoo! FinanceRead the rest

Mast Therapeutics Announces Adjournment Of Special Stockholders Meeting

Yahoo! FinanceRead the rest

Mast Therapeutics Announces Possible Adjournment Of Special Stockholders Meeting To Solicit Additional Votes For Merger With Savara

PR NewswireRead the rest

Mast Therapeutics Inc. (NYSEMKT:MSTX) Embraces Savara Inc. as the Best Tactical Strategy

Wall Street PRRead the rest

BRIEF-Mast reminds stockholders to vote for proposed merger with Savara

ReutersRead the rest

Mast Reminds Stockholders To Vote For The Proposed Merger With Savara

Yahoo! FinanceRead the rest

Mast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market

PR NewswireRead the rest

Mast Therapeutics Inc (NYSEMKT:MSTX) Poised For A Turnaround

Insider FinancialRead the rest

Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara

PR NewswireRead the rest

Mast Therapeutics, Inc. (NYSEMKT:MSTX) Files An 8-K Regulation FD Disclosure

Market ExclusiveRead the rest

U.S. Patents Awarded to Inventors in Indiana

Targeted News ServiceRead the rest

Savara Pharmaceuticals: 2 Biotech Stocks News And Price Trends: Biostage (NASDAQ:BSTG), MAST Therapeutics (NYSEMKT:MSTX)

Voice RegistrarRead the rest

Mast Therapeutics, Inc — Bulls & Bears

Seneca GlobeRead the rest

Savara: Time To Put On The Watch List? – MAST Therapeutics, Inc. (NYSEMKT:MSTX)

Voice RegistrarRead the rest

Time To Put On The Watch List? – Mast Therapeutics, Inc. 

Voice RegistrarRead the rest

A Glimpse into the Mast Therapeutics Inc (MSTX) and Savara Merger

Smarter AnalystRead the rest

Canaccord Cheers Mast Therapeutics Inc (MSTX) In Light Of Strategic Merger With Savara

Smarter AnalystRead the rest

Mast Therapeutics, Inc. (NYSE:MSTX) and Savara Inc entered into definitive merger agreement

Benchmark MonitorRead the rest

Mast Therapeutics Inc (NYSEMKT:MSTX) Signs A Merger Agreement With Savara Inc.

Financial TrendsRead the rest

Mast Therapeutics (MSTX) to Merge with Savara

StreetInsider.comRead the rest

Savara and Mast to Merge to Progress Clinical Pipeline of Inhaled Drugs

Genetic Engineering & Biotech NewsRead the rest

Savara: Another public company is on Austin’s horizon, this time a drugmaker heading for NYSE

Austin Business JournalRead the rest

Mast Therapeutics To Merge With Savara Inc. (MSTX)

InvestopediaRead the rest

Mast Therapeutics And Savara Sign Merger Agreement

click hereRead the rest

Mast Therapeutics And Savara Sign Merger Agreement

click hereRead the rest

Savara Pharmaceuticals Appoints David L. Lowrance As CFO

click hereRead the rest

Savara Pharmaceuticals Appoints David L. Lowrance As CFO

click hereRead the rest

Savara Builds on Serendex Acquisition by Advancing Inhaled Therapies for Lung Diseases, Infections

click hereRead the rest

Savara Fully Acquires Serendex, Readies Phase 3 Trial of Inhaled Antibiotic for CF Lung Infections

click hereRead the rest

Savara Completes Acquisition Of Serendex

click hereRead the rest

Savara Pharmaceuticals Buys Serendex Pharmaceuticals

click hereRead the rest

Austin biotech Savara adds two lung drugs in deal for Serendex

click hereRead the rest

Savara: Austin pharma company makes play for 2 new drugs

click hereRead the rest

Inhaled-Drug Maker Savara Buys European Biotech With Two Candidates

click hereRead the rest

Austin’s Savara Pharmaceuticals acquires Denmark firm

click hereRead the rest

Specialty pharma startup Savara buys up a pair of orphan respiratory candidates

click hereRead the rest

Savara Pharmaceuticals Acquires Serendex Pharmaceuticals

click hereRead the rest

Savara Pharma acquires Denmark-based Serendex Pharma

click hereRead the rest

Savara Pharmaceuticals Buys Serendex Pharmaceuticals

click hereRead the rest

Austin pharma company Savara makes play for 2 new drugs

click hereRead the rest

7 Tips for Raising $39 M from 350 Angels by Rob Neville of Savara

7 TIPS FOR RAISING $39M FROM 350 ANGEL INVESTORS BY ROB NEVILLE OF SAVARA

Rob Neville, CEO of Savara Pharmaceuticals raised over $39M from 350 Angel investors, representing 30 Angel groups from around the world. Neville believes that there are hordes of wealthy individuals looking to invest their money in promising startups.

Read the rest